Two decentralized trials startups prove they're not immune to broader wave of biotech layoffs
After raising heaps of capital during the first two years of the Covid-19 pandemic to help biopharmas shift to virtual clinical studies, a few decentralized clinical trials providers have conducted layoffs in recent months as they adjust business priorities, Endpoints News has learned.
That includes privately held Medable, which disclosed a $304 million Series D last October, and Science 37, which also began trading last October after a SPAC merger.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.